Adaptive Biotechnologies Corporation announced a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP, a product that combines the sequencing and mapping capabilities of Adaptive's proprietary immune medicine platform to map T-cell receptors (TCRs) to antigens, across AstraZeneca's oncology portfolio. Under this collaboration, AstraZeneca will provide biological samples from patients with cancer; Adaptive will sequence these samples and deliver TCR-antigen mapping data using its growing and dynamic clinical immunomics database of more than 58 billion immune cell receptors and thousands of antigens. This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions.

Additionally, mapping of unique TCRs to antigens at scale can provide powerful information regarding the potential for early and accurate detection of a disease and the specificity of a given patient's immune response to therapy. Adaptive will receive from AstraZeneca quarterly payments plus sequencing and data mapping fees. In addition, AstraZeneca has an option to enter into a separate agreement with Adaptive for the development and commercialization of a companion diagnostic or therapeutic application based on T-MAP data.

Specific financial terms of the agreement will not be disclosed. The scope of this non-exclusive, pan-portfolio oncology collaboration may be expanded to cover additional therapeutic areas, including autoimmunity and infectious diseases.